95 related articles for article (PubMed ID: 19373664)
1. mTOR inhibition and adult T-cell leukemia.
Hirase C; Maeda Y; Yamaguchi T; Miyatake J; Kanamaru A
Leuk Lymphoma; 2009 Apr; 50(4):645-7. PubMed ID: 19373664
[No Abstract] [Full Text] [Related]
2. Prospects for mTOR targeting in adult T cell leukemia.
Altman JK; Platanias LC
Leuk Lymphoma; 2009 Apr; 50(4):525-6. PubMed ID: 19373648
[No Abstract] [Full Text] [Related]
3. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells.
Park S; Sim H; Lee K
BMB Rep; 2016 Jan; 49(1):63-8. PubMed ID: 26497580
[TBL] [Abstract][Full Text] [Related]
6. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
8. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
10. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Zheng J; Zou X; Yao J
Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
[TBL] [Abstract][Full Text] [Related]
11. [Advances on PI3K/Akt/mTOR signalling pathway in malignancies].
Yu BH; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2005 Oct; 34(10):674-6. PubMed ID: 16536284
[No Abstract] [Full Text] [Related]
12. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
[TBL] [Abstract][Full Text] [Related]
15. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
Cao X; Kambe F; Moeller LC; Refetoff S; Seo H
Mol Endocrinol; 2005 Jan; 19(1):102-12. PubMed ID: 15388791
[TBL] [Abstract][Full Text] [Related]
17. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
18. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
19. Rigosertib is more potent than wortmannin and rapamycin against adult T-cell leukemia-lymphoma.
Ghorbanzadeh Neghab M; Jalili-Nik M; Soltani A; Afshari AR; Hassanian SM; Rafatpanah H; Rezaee SA; Sadeghnia HR; Ataei Azimi S; Mashkani B
Biofactors; 2023; 49(6):1174-1188. PubMed ID: 37345860
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas.
Darwiche N; Sinjab A; Abou-Lteif G; Chedid MB; Hermine O; Dbaibo G; Bazarbachi A
Int J Cancer; 2011 Aug; 129(4):993-1004. PubMed ID: 21064094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
